Activity of Fluoroquinolones and Proton Pump Inhibitors against Resistant Oral Bacterial Biofilms, in silico and in vitro Analysis.

Publisher: Polskie Towarzystwo Mikrobiologów Country of Publication: Poland NLM ID: 101229003 Publication Model: eCollection Cited Medium: Internet ISSN: 2544-4646 (Electronic) Linking ISSN: 17331331 NLM ISO Abbreviation: Pol J Microbiol Subsets: MEDLINE

Original Publication: Warsaw, Poland : Polskie Towarzystwo Mikrobiologów, 2004-

Biofilms*/drug effects ; Proton Pump Inhibitors*/pharmacology ; Anti-Bacterial Agents*/pharmacology ; Fluoroquinolones*/pharmacology ; Microbial Sensitivity Tests* ; Staphylococcus aureus*/drug effects ; Staphylococcus aureus*/physiology; Humans ; Drug Resistance, Bacterial ; Mouth/microbiology ; Staphylococcus epidermidis/drug effects ; Staphylococcus epidermidis/physiology

Oral bacterial infections are a great health concern worldwide especially in diabetic patients. Emergence of antimicrobial resistance with reference to biofilms in oral cavity is of great concern. We investigated antibiotics combination with proton pump inhibitors against oral clinical isolates. The strains were identified as Staphylococcus epidermidis and Staphylococcus aureus by the 16S rRNA gene sequencing. In molecular docking, ciprofloxacin, levofloxacin, and omeprazole best fit to active pockets of transcriptional regulators 4BXI and 3QP1. None of the proton pump inhibitors were active against S. epidermidis , whereas omeprazole showed significant inhibition (MIC 3.9 μg/ml). Fluoroquinolones were active against both S. epidermidis and S. aureus . In combination analysis, a marked decrease in minimum inhibitory concentration was noticed with omeprazole (MIC 0.12 μg/ml). In antiquorum sensing experiments, a significant inhibitory zone was shown for all fluoroquinolones (14-20 mm), whereas among proton pump inhibitors, only omeprazole (12 ± 0.12 mm) was active against Chromobacterium violaceum . In combination analysis, a moderate increase in antiquorum sensing activity was recorded for ciprofloxacin, ofloxacin, and proton pump inhibitors. Further, significant S. aureus biofilm eradication was recorded using of ciprofloxacin, levofloxacin, and omeprazole combination (78 ± 2.1%). The time-kill kinetic studies indicated a bactericidal effect by ciprofloxacin: levofloxacin: omeprazole combination over 24 hrs. It was concluded that fluoroquinolone combined with omeprazole could be an effective treatment option for eradicating oral bacterial biofilms.
(© 2024 Muhammad Kamran et al., published by Sciendo.)

Infect Control Hosp Epidemiol. 2011 Nov;32(11):1109-15. (PMID: 22011539)
Microbiol Mol Biol Rev. 2013 Mar;77(1):73-111. (PMID: 23471618)
Mol Cell. 2011 Apr 22;42(2):199-209. (PMID: 21504831)
Curr Gastroenterol Rep. 2008 Dec;10(6):528-34. (PMID: 19006606)
Biomed Res Int. 2018 Dec 31;2018:6498932. (PMID: 30687755)
Biotechnol Lett. 2006 Jan;28(1):55-9. (PMID: 16369876)
Int J Oral Maxillofac Implants. 2001 Mar-Apr;16(2):201-7. (PMID: 11324208)
Periodontol 2000. 2012 Oct;60(1):15-39. (PMID: 22909104)
Clin Infect Dis. 2001 Oct 15;33(8):1387-92. (PMID: 11565080)
Front Microbiol. 2021 Jul 05;12:700494. (PMID: 34290689)
Am J Infect Control. 2015 Jan;43(1):35-7. (PMID: 25564121)
Dent J (Basel). 2018 Apr 16;6(2):. (PMID: 29659479)
Br Dent J. 2008 Nov 8;205(9):489-91. (PMID: 18997702)
BMC Oral Health. 2021 Sep 16;21(1):450. (PMID: 34530810)
PLoS Pathog. 2012;8(4):e1002623. (PMID: 22496649)
J Microbiol Immunol Infect. 2011 Apr;44(2):144-8. (PMID: 21439518)
Int Dent J. 2014 Dec;64(6):295-6. (PMID: 25417784)
Diagn Microbiol Infect Dis. 2007 Nov;59(3):347-9. (PMID: 17662552)
Biomedicines. 2022 May 18;10(5):. (PMID: 35625906)
Genes Dev. 1995 Nov 15;9(22):2859-69. (PMID: 7590259)
Evid Based Complement Alternat Med. 2017;2017:4534350. (PMID: 29234399)
J Med Microbiol. 2008 Jan;57(Pt 1):95-99. (PMID: 18065673)
mBio. 2013 Jul 23;4(4):. (PMID: 23882012)
Microorganisms. 2023 Jan 20;11(2):. (PMID: 36838244)
Int J Dent Hyg. 2011 Feb;9(1):43-52. (PMID: 21226850)
Front Microbiol. 2018 Feb 20;9:270. (PMID: 29515550)
Biomolecules. 2019 Dec 12;9(12):. (PMID: 31842463)
Emerg Infect Dis. 2001 Mar-Apr;7(2):337-41. (PMID: 11294736)
Nucleic Acids Res. 2014 Nov 10;42(20):12523-36. (PMID: 25352558)
Nanomedicine (Lond). 2016 Apr;11(8):873-9. (PMID: 26987892)
J Periodontol. 2005 Nov;76 Suppl 11S:2075-2084. (PMID: 29539051)
J Comput Chem. 2010 Jan 30;31(2):455-61. (PMID: 19499576)
Curr Opin Biotechnol. 2014 Apr;26:1-6. (PMID: 24679251)
J Microbiol Methods. 2004 Sep;58(3):351-60. (PMID: 15279939)
Lancet. 2005 Nov 19;366(9499):1809-20. (PMID: 16298220)
Microorganisms. 2020 Aug 22;8(9):. (PMID: 32842696)
J Appl Genet. 2016 May;57(2):225-38. (PMID: 26294280)
Bioorg Med Chem Lett. 2009 Aug 1;19(15):4364-6. (PMID: 19523823)
J Antimicrob Chemother. 2000 Jul;46 Suppl T1:17-24. (PMID: 10997595)
J Chem Inf Model. 2011 Oct 24;51(10):2778-86. (PMID: 21919503)
Sci Adv. 2016 Mar 25;2(3):e1501240. (PMID: 27051863)
Front Microbiol. 2019 Jun 07;10:1100. (PMID: 31231316)
Antimicrob Agents Chemother. 1996 Mar;40(3):621-6. (PMID: 8851582)
Antibiotics (Basel). 2021 Dec 08;10(12):. (PMID: 34943716)
J Pharm Pharmacol. 2002 Mar;54(3):341-7. (PMID: 11902800)
Molecules. 2015 Jul 28;20(8):13705-24. (PMID: 26225951)

Keywords: antiquorum sensing; fluoroquinolones; molecular docking; proton pump inhibitors; synergism

0 (Proton Pump Inhibitors)
0 (Anti-Bacterial Agents)
0 (Fluoroquinolones)

Date Created: 20240913 Date Completed: 20240913 Latest Revision: 20240915

20240915

PMC11395420

10.33073/pjm-2024-028

39268954